AI Article Synopsis
- EPHA2 is a receptor that is highly present in aggressive cancers, making it a strong candidate for antibody-based treatments, particularly in melanoma.
- Researchers created and tested three monoclonal antibodies to EPHA2, using various assays to assess their effectiveness in inhibiting tumor cell migration and growth.
- The study found that one of the antibodies, SHM16, not only reduced metastatic behavior in melanoma cells but also significantly inhibited cell growth when coupled with a toxin, highlighting EPHA2's potential as an effective target for melanoma therapies.
Article Abstract
Background/aim: EPH receptor A2 (EPHA2) is highly expressed in aggressive types of human cancer, and is expected to be an excellent target molecule for antibody treatments. In this study, we investigated the therapeutic potential of antibody to EPHA2 against melanoma in vitro.
Materials And Methods: We generated three monoclonal antibodies (mAbs) to EPHA2 and examined cell-surface expression by flow cytometry. To investigate the ability to inhibit tumor cell migration therapy with mAbs to EPHA2, we performed a wound scratch assay and invasion assay. We investigated the therapeutic effects of immunotoxins consisting of toxin-conjugated EPHA2 mAbs.
Results: All human melanoma cell lines studied expressed EPHA2. Like natural ligand ephrin-A1, one of EPHA2 mAbs, SHM16, inhibited metastatic behavior of cells, such as migration and invasion. In addition, drastic growth inhibition and cytotoxicity were found using immunotoxin-conjugated SHM16.
Conclusion: These observations indicate a promising role for EPHA2 as a target in antibody treatments for melanoma, and demonstrate the potential therapeutic effects of an agonistic antibody to EPHA2.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.21873/anticanres.12592 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!